Search the Newsreel

Edgewise Therapeutics (NASDAQ:EWTX) CEO Kevin Koch Sells 17,971 Shares of Stock

Badger Meter Raises Quarterly Dividend to $0.44 a Share From $0.40, Payable Sept. 11 to Holders of Record Aug. 28

Badger Meter has increased its quarterly dividend from $0.40 to $0.44 per share. The dividend is scheduled to be paid on September 11, 2026, to shareholders who are on record as of August 28, 2026. This announcement reflects a positive financial adjustment for the …

Edgewise Therapeutics (NASDAQ:EWTX) CMO Sells 6,522 Shares

Edgewise Therapeutics CMO Joanne Donovan recently sold 6,522 shares of EWTX stock for $285,989.70 to cover tax withholding obligations on vested equity awards, reducing her holdings by 36.1%. Despite this insider sale and a quarterly earnings miss, the company's shares rose 2.3%, and analysts …

Insider Selling: Edgewise Therapeutics (NASDAQ:EWTX) Insider Sells 5,901 Shares

Edgewise Therapeutics (NASDAQ:EWTX) insider Alan Russell sold 5,901 shares of the company's stock on August 12th, 2026, totaling approximately $258,051. This sale was conducted to cover tax withholding obligations related to vested equity awards. Despite this insider selling, analysts maintain a "Moderate Buy" consensus …

Edgewise Therapeutics (EWTX) CSO gets 97,500-share equity awards, sells shares for taxes

Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, reported equity transactions on August 12, 2026, which included exercising Restricted Stock Units and selling 5,901 shares to cover tax withholding obligations. Additionally, Russell received new equity awards comprising 32,500 RSUs and a stock option for …

Edgewise Therapeutics (NASDAQ:EWTX) General Counsel Sells $219,801.12 in Stock

Edgewise Therapeutics General Counsel John Moore sold 5,016 shares of EWTX stock worth $219,801.12 to cover tax withholding obligations from vested equity awards, reducing his direct ownership by 22.08%. The company's stock is trading near its 52-week high, and despite missing recent earnings expectations, …

Edgewise Therapeutics (EWTX) grants CFO 24,375 RSUs and 48,750-share option

Edgewise Therapeutics (EWTX) has granted its CFO, Michael Nofi, 24,375 Restricted Stock Units (RSUs) and an option for 48,750 shares of common stock. The RSUs vest in four equal annual installments starting August 12, 2027, and the stock options vest monthly over 48 months …

RA Capital’s 7.8% Edgewise Therapeutics (EWTX) stake totals 8.39M shares

RA Capital Management, L.P. and its affiliated parties have reported a 7.8% stake in Edgewise Therapeutics, Inc. (EWTX), totaling 8,392,730 shares of common stock. This ownership is held by RA Capital Healthcare Fund, L.P., with RA Capital having shared voting and dispositive power over …

Edgewise Therapeutics (EWTX) grants 50,000 RSUs and 100,000 options to CBO

Edgewise Therapeutics reported that its Chief Business Officer, Derakhshan Behrad, received equity awards comprising 50,000 Restricted Stock Units (RSUs) and a stock option for 100,000 shares. Behrad also had 5,781 and 7,500 RSUs convert into common stock on August 12, 2026, and subsequently sold …

Ridgepost Capital Breaks Below 200-Day Moving Average - Notable for RPC

In trading on Friday, shares of Ridgepost Capital Inc Class A (Symbol: RPC) crossed below their 200 day moving average of $8.83, changing hands as low as $8.64 per share. Ridgepost Capital Inc Class A shares are currently trading off about 2.7% on the …

Badger Meter Raises Dividend 10% Representing 34 Years of Consecutive Annual Dividend Growth

MILWAUKEE, August 14, 2026--(BUSINESS WIRE)--The Board of Directors of Badger Meter, Inc. (NYSE: BMI) today authorized a 10% increase in its quarterly common stock dividend to $0.44 per share from $0.40 per share. The increased dividend is payable September 11, 2026, to shareholders of …

Bridgemarq Real Estate Services, Inc. (BRE) Q1 2025 Earnings Report - Results, Call & Slides

Chain Bridge I (OTC: CBGGF) reports loss, deficits and SPAC deadline risk

Chain Bridge I Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Bridgeline Digital Ties Record New Customer Wins as AI Search Demand Accelerates

Bridgeline Digital reported strong fiscal third-quarter 2026 results, tying a company record with nine new customer wins and expanding relationships with ten existing accounts, driven by accelerating demand for its AI-powered HawkSearch platform. Core product revenue grew 13% on a trailing twelve-month basis, now …

Edgewise Therapeutics (EWTX): Baker Bros. discloses 3.4% ownership in Schedule 13G/A

StoneBridge Acquisition II Cuts Administrative Costs Via Waiver

Top Ridgepost Capital (RPC) Competitors 2026

StoneBridge Acquisition II Corp 2Q 2026: Net income $352348 EPS $0.04— 10-Q Summary

StoneBridge Acquisition II (APAC) outlines $59M trust, income and going concern risk

Seabridge Gold (NYSE: SA) posts $117.5M Q2 profit and advances KSM work

Seabridge Gold reported a significant increase in Q2 2026 net income to $117.5 million, largely due to gains from spinning out the Courageous Lake project. The company is actively advancing its KSM project with major field programs and infrastructure development, supported by a newly …

Suncor or Enbridge? Here’s the Better Dividend Stock This Year

This article compares Suncor Energy and Enbridge as dividend stock investments. While Enbridge offers a higher current yield and more stable operations, Suncor is highlighted for its strong balance sheet, potential upside from elevated energy prices, and aggressive share buybacks, making it the preferred …

Enbridge Inc. stock rises Friday, outperforms market

Enbridge Inc. (ENB) saw its stock rise by 0.16% to C$70.61 on Friday, outperforming the broader Canadian market where the S&P/TSX Composite Index fell by 0.08%. Despite this gain, the company's stock closed 12.4% below its 52-week high of C$80.65, achieved on May 22nd.

JPMorgan Chase & Co. Has Lowered Expectations for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price

Seabridge Gold (NYSE:SA) Trading Up 6.1% - What's Next?

WaterBridge Infrastructure LLC (WBI) Stock Price, News, Quote & History

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

One of the more high-flying stocks in the U.S. biotech sector these days is genetic-disease-focused BridgeBio Pharma (NASDAQ: BBIO). That's due almost entirely to the outperformance of its Attruby heart medication. If the generally bullish analyst sentiment on the company is anything to go …

BridgeBio Pharma's Transition to Rare Disease 'Commercial Powerhouse' On Track, RBC Says

BridgeBio Pharma's (BBIO) transition into a rare disease "commercial powerhouse" is on track and poised to accelerate, RBC Capital Markets said in a Friday note.The company's Attruby drug is gaining traction in first-line treatment settings, while the market for the drug Silver Upgrade to …

Broadridge (BR) CHRO granted 2,172 RSUs, total holdings now 7,680 shares

Broadridge Financial Solutions, Inc. (BR) reported that its Corporate VP and CHRO, Richard John Stingi, was granted 2,172 Restricted Stock Units (RSUs) as part of the company's 2018 Omnibus Award Plan. These RSUs will vest and convert into common stock on October 1, 2026, …

Broadridge (BR) CFO receives 466-share RSU award after three-year performance period

Broadridge Financial Solutions, Inc. (BR) CFO Ashima Ghei was granted 466 Restricted Stock Units (RSUs) as determined by a three-year performance period. These RSUs will vest and convert into common stock on October 1, 2026, bringing her total direct holdings to 6,027 shares. The …

Seabridge Gold (NYSE: SA) gains $151.7M from spin-out, advances giant KSM project

Seabridge Gold reported strong financial results for the three and six months ended June 30, 2026, primarily due to a $151.7 million gain from the spin-out of its Courageous Lake Project into Valor Gold Corp. The company achieved a net income of $117.5 million …

5 Revealing Analyst Questions From Ridgepost Capital’s Q2 Earnings Call

Analyst Estimates: Here's What Brokers Think Of BridgeBio Pharma, Inc. (NASDAQ:BBIO) After Its Second-Quarter Report

This article analyzes what brokers think of BridgeBio Pharma, Inc. (NASDAQ:BBIO) following its second-quarter report. It would likely detail analyst ratings, price targets, and any changes in sentiment post-earnings, providing insights into the company's financial performance and future outlook from an investment perspective.

WaterBridge (WBI) Raised Guidance Again, So Why Did Shares Slip?

WaterBridge Infrastructure (NYSE:WBI) just posted record quarterly revenue, raised its full-year outlook for the second straight quarter, and closed a wave of acquisitions that doubled its waste management footprint in the Delaware Basin. Yet the stock fell 1.73% around the release. For a produced …

BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base

BridgeBio Pharma, Inc. announced the pricing of an oversubscribed secondary offering of 5,000,000 shares of its common stock by KKR Genetic Disorder L.P. The company itself is not selling shares and will not receive any proceeds from the offering. This transaction aims to further …

KKR to Sell 5M BridgeBio Shares; Company Receives No Proceeds

BridgeBio Pharma announced the pricing of a secondary offering of 5,000,000 shares of its common stock by existing shareholder KKR Genetic Disorder L.P. BridgeBio will not issue any shares or receive any proceeds from this transaction, which is expected to close on August 17, …